National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

It is licensed for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.

Rapid Review

Commenced Completed Outcome
28/04/2014 16/07/2014 Full Pharmacoeconomic Evaluation Recommended at the
Submitted Price.

The HSE has approved reimbursement following confidential price negotiation.